Loxo Oncology Inc to Present LOXO-101 Phase 1 Larotrectinib Data Presented at 2017 ASCO
Llamada en conferencia Loxo Oncology Inc
Loxo Oncology Inc Conference call or earnings call will be held on 04-jun-2017 During the earnings conference call's session Loxo Oncology Inc will provide updated information and financial status.
In order to join the audio conference call the bridge access number and key in the PIN code, Contact Loxo Oncology Inc for this information
Schedule a conference call with QCONF and get 5 free conference calls.
Loxo Oncology is a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers. Our pipeline focuses on cancers that are uniquely dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect. We believe that the most selective, purpose-built medicines have the highest probability of maximally inhibiting the intended target, thereby delivering best-in-class disease control and safety. Our management team seeks out experienced industry partners, world-class scientific advisors and innovative clinical-regulatory approaches to deliver new cancer therapies to patients as quickly and efficiently as possible. As genetic testing in cancer becomes more routine, we are learning that cancers arising in diverse sites in the body may share the same type of genetic alterations.Leer más Llamada en conferencia